I det kliniske fase 3- forsøg havde disse patienter større risiko for blødning, herunder fatal blødning, sammenlignet med patienter < 75 år.
The use of Efient in patients ≥ 75 years of age is generally not recommended and should only be undertaken with caution after a careful individual benefit/ risk evaluation by the prescribing physician indicates that benefits in terms of prevention of ischaemic events outweigh the risk of serious bleedings.